NEW YORK (TheStreet) -- Shares of stem cell therapy developer Neuralstem (CUR - Get Report) rose 4.62% to $2.72 on higher-than-average volume in afternoon trading Wednesday in sympathy with peer company Brainstorm Cell Therapeutics (BCLI) …
The Street · 12/31/2014
Neuralstem Inc. (CUR) established a new 52-week low yesterday, and could be a company to watch at the open. After opening at $1.60, Neuralstem Inc. dropped to $1.52 for a new 52-week low. By the closing bell, the company's stock was at $1.59 a share …
Equities · 5/29/2015
Neuralstem, Inc. (CUR)’s monthly performance stand at -10.65% and has an analyst rating of 2.4 (Click To Expand Current Stock Data:) Anthem, Inc. (ANTM) of the Healthcare sector (Health Care Plans) is down -1.14% already this morning, a change … · 6/3/2015
More from Bing News
Small cap ALS and stem cell stock Brainstorm Cell Therapeutics Inc (NASDAQ ... CYTK), Neuralstem, Inc (NYSEMKT: CUR) and NeoStem Inc (NASDAQ: NBS). However, Brainstorm Cell Therapeutics does have a history of being the subject of paid …
Smallcap Network · ByJohn Udovich · 1/2/2015
“This motion represents a possible new avenue to challenge Bass’s effort to use the IPR procedure to lower the stock prices of targeted pharmaceutical companies,” Cary Miller and Matthew I. Kreeger, two Morrison … · 6/22/2015
Approximately 16.8% of the company’s stock are short sold. Based on an average daily trading volume, of 627,492 shares, the days-to-cover ratio is currently 23.2 days. A number of analysts have recently weighed in on CUR shares. Analysts at Brean …
Mideast Times · 6/10/2015
Jul 2 2015 - Qatar- QSE lost 152 points, back in negative turf, Gulf Times (MENAFN - Gulf Times) Qatar Stock Exchange was back in the negative turf and its key index lost 152 points mainly due to profit booking by foreign institutions.Telecom, realty and ...
MENAFN · 1 day ago
Neuralstem, Inc. (NYSEMKT:CUR) stock closed at $2.37 in last session with the total traded volume of 11.25 Million. The Financial Institutional ownership of the firm was 23.70% while by insiders was 0.00%. A federal judge said Citigroup Inc. (NYSE ... · 3/13/2015
One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. Neuralstem currently has a consensus rating of “Buy” and a consensus price target of $7.00. Neuralstem (NYSE:CUR) opened at 1.63 on … · 5/28/2015
Todd Campbell: One of the most exciting things about investing in biotech stocks is discovering companies that are ... For more than a year now, excitement in the stock has run high, with early and midstage clinical trials suggesting possible treatment ...
The Motley Fool · ByBrian Orelli · 3/11/2015
Related Searches